Nureca Limited has informed the exchange regarding Press Release
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Nureca Limited reported strong Q4 FY25 results with revenue surging 87% to ₹31.74 crore (from ₹16.97 crore in Q4 FY24). Full-year FY25 revenue grew 19.3% to ₹109.66 crore. The company turned profitable at the EBITDA level, with Q4 EBITDA at ₹3.2 crore (up 156% from a loss of ₹5.6 crore) and full-year EBITDA at ₹4.9 crore (up 1,489% from ₹0.3 crore). Its manufacturing arm Nureca Technologies completed USFDA registration for medical devices, enabling export expansion from its Mohali facility. The company expanded its direct-to-consumer channel and partnered with Swiggy Instamart, joining existing listings on Blinkit and Zepto. FY26 priorities include scaling Punjab manufacturing, deepening quick commerce presence, launching new health and wellness products, and expanding into North American and Middle Eastern markets.
Strong quarterly growth and return to EBITDA profitability signal improving business momentum, which is positive for shareholders. The USFDA certification and quick commerce partnerships open new revenue streams, though execution on FY26 strategic priorities will be key for sustained growth.